Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Immunome, Inc. (IMNM : NSDQ)

• Company Description    Immunome, Inc. is a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Immunome, Inc. is based in Exton, United States. Number of Employees: 177

• Price / Volume Information    Yesterday's Closing Price: $22.21 Daily Weekly Monthly 20 Day Moving Average: 1,460,665 shares Shares Outstanding: 113.25 (millions) Market Capitalization: $2,515.28 (millions) Beta: 2.07 52 Week High: $27.65 52 Week Low: $8.67 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 14.48% 13.64% 12 Week -3.18% -5.83% Year To Date 3.40% -5.32%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 18702 N. CREEK PARKWAY SUITE 100 - BOTHELL,WA 98011 USA ph: 425-939-7410 fax: - investors@immunome.com http://www.immunome.com

• General Corporate Information    Officers Clay Siegall - President; Chief Executive Officer and Director Max Rosett - Chief Financial Officer Isaac Barchas - Director Jean-Jacques Bienaime - Director James Boylan - Director Peer Information Immunome, Inc. (CORR.) Immunome, Inc. (RSPI) Immunome, Inc. (CGXP) Immunome, Inc. (BGEN) Immunome, Inc. (GTBP) Immunome, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45257U108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/05/26 Share - Related Items Shares Outstanding: 113.25 Most Recent Split Date: (:1) Beta: 2.07 Market Capitalization: $2,515.28 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.53 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.06 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.27 Price/Cash Flow: - Price / Sales: 199.80 EPS Growth vs. Year Ago Period: 7.69% vs. Previous Quarter: 36.00% Sales Growth vs. Year Ago Period: 69.84% vs. Previous Quarter: 37.22% ROE 06/30/26 - - 03/31/26 - -51.15 12/31/25 - -57.61 ROA 06/30/26 - - 03/31/26 - -47.32 12/31/25 - -52.39 Current Ratio 06/30/26 - - 03/31/26 - 21.68 12/31/25 - 14.69 Quick Ratio 06/30/26 - - 03/31/26 - 21.68 12/31/25 - 14.69 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - -5,593.85 12/31/25 - -3,059.99 Book Value 06/30/26 - - 03/31/26 - 5.20 12/31/25 - 5.75 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©